- Home
- SAP vs AZN Comparison
SAP vs AZN Comparison
Compare SAP & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAP | AZN |
|---|---|---|
| Founded | 1972 | 1992 |
| Country | Germany | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.4B | 283.9B |
| IPO Year | 1998 | 1993 |
Fundamental Metrics
Financial Performance| Metric | SAP | AZN |
|---|---|---|
| Price | $230.58 | $92.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $340.75 | N/A |
| AVG Volume (30 Days) | 1.8M | ★ 8.2M |
| Earning Date | 01-29-2026 | 02-10-2026 |
| Dividend Yield | 0.82% | ★ 1.65% |
| EPS Growth | ★ 159.50 | 45.02 |
| EPS | ★ 7.07 | 6.02 |
| Revenue | $42,818,256,487.00 | ★ $58,127,000,000.00 |
| Revenue This Year | $9.60 | $11.40 |
| Revenue Next Year | $10.48 | $6.06 |
| P/E Ratio | $32.62 | ★ $30.42 |
| Revenue Growth | 9.70 | ★ 13.52 |
| 52 Week Low | $220.89 | $61.24 |
| 52 Week High | $313.28 | $96.51 |
Technical Indicators
Market Signals| Indicator | SAP | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 39.29 | 51.78 |
| Support Level | $220.89 | $89.04 |
| Resistance Level | $255.90 | $96.43 |
| Average True Range (ATR) | 4.96 | 1.83 |
| MACD | -1.50 | -0.40 |
| Stochastic Oscillator | 27.93 | 51.27 |
Price Performance
Historical ComparisonAbout SAP SAP SE ADS
Founded in Germany in 1972 by former IBM employees, SAP is the world's largest provider of enterprise application software. Known as the leader in enterprise resource planning software, SAP's portfolio also includes software for supply chain management, procurement, travel and expense management, and customer relationship management, among others. The company operates in more than 180 countries and has more than 400,000 customers, approximately 80% of which are small to medium-size enterprises.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.